Cardiovascular and immunology products

Merck & Co.’s (MRK) cardiovascular products portfolio includes four drugs: Atozet, Adempas, Zetia, and Vytorin. Its immunology products include Simponi and Remicade.

Merck & Co.’s Cardiovascular and Immunology Products in 3Q17

The above chart compares the revenues for key products from Merck’s immunology and cardiovascular portfolio for the last eight quarters.

Cardiovascular franchise

In Merck’s cardiovascular product portfolio, Adempas reported revenues of $70 million in 3Q17 compared to $48 million in 3Q16. Atozet reported revenues of $59 million in 3Q17 compared to $39 million in 3Q16.

Zetia and Vytorin are used to lower LDL (low-density lipoprotein) cholesterol levels. They decreased ~52% in operating revenues to $462 million in 3Q17 compared to $944 million in 3Q16.

Immunology franchise

Merck’s immunology product portfolio includes Remicade and Simponi.

Merck holds the marketing rights for Remicade only in European markets. Johnson & Johnson (JNJ) holds marketing rights for Remicade for major countries outside Europe. Remicade reported a decline of 31% in revenues to $214 million in 3Q17 compared to $311 million in 3Q16, driven by lower sales of Remicade due to competition from generic products and biosimilars. Revenues are expected to decline further as patients shift more to biosimilars.

Simponi reported 13% growth in revenues to $219 million in 3Q17 compared to $193 million in 3Q16.

The Vanguard Health Care ETF (VHT) holds 4.1% of its total investments in Merck (MRK), 4.2% in AbbVie (ABBV), 2.8% in Bristol-Myers Squibb (BMY), and 2.6% in Abbott Laboratories (ABT).

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.

172.31.38.64